Clinical Trial Search

Primary: Time to Progression (TTP) — 164; 112 days

Primary: Rate of Adverse Events (AE) ≥ Grade 3 (CTCAE 5.0) Excluding Palmar-plantar Erythrodysesthesia — 16 Participants

Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM

Primary: Overall Survival — 289; 259 Days

Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006

Primary: Response Rate by Recist Criteria — 6 participants

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events…

Primary: Overall Response Rate — 6; 30; 17; 0 Participants

Primary: Time to Progression (TTP) — 3.5 months

Primary: Overall Survival (OS) — 10.2; 8.0 months — p=0.0049

Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients

Primary: Overall Survival (OS) - Stratified Analysis, Randomized Portion — 12.7; 9.7 months — p=0.2872

Primary: Median Overall Survival (OS) Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular…

Primary: Overall Survival — 8.9; 10.5 month — p=0.24

Primary: Overall Survival (OS) — 324; 241 days — p=0.00583

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months

Primary: Disease Control Rate (DCR) in Study Participants — 46 percentage of participants

Primary: Progression Free Survival (PFS) — 43 months

Primary: Median Time to Progression (TTP) — 3.7 months

Primary: Overall Survival (OS) — 7.56; 7.33 Months

Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg

Primary: Overall Survival (OS) — 7.69; 7.75 months — p=0.248

Primary: Overall Survival — 8.7; 6.8 months

Primary: Overall Survival (OS) — 237; 323 days — p== 0.000017

Primary: 24-Week Progression-Free Survival Rate (PFSR) — 59.8; 16.7 percentage of participants

Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536

Primary: Objective Response Rate — 11.9; 16.7 percentage of participants